Rosuvastatin vs Tamoxifen
FDA Approved vs FDA Approved
avoid Mechanism-based · 75% Both Rosuvastatin and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Rosuvastatin Tamoxifen
Weight 481.54 Da 371.51 Da
Half-life ~19 hours ~5-7 days
Type Synthetic statin (C22H28FN3O6S-Ca) Triphenylethylene-derived selective estrogen receptor modulator
Key Benefits
Rosuvastatin
01 Most potent statin available, with LDL reductions of 45-63% depending on dose
02 Long half-life (19 hours) allows flexible once-daily dosing at any time of day
03 Effective at counteracting AAS-induced lipid disturbances, particularly elevated LDL
04 Significant reduction in high-sensitivity CRP (30-50%), indicating anti-inflammatory benefit
05 Hydrophilic structure provides hepatic selectivity with potentially fewer muscle side effects
06 Raises HDL cholesterol by 8-14%, partially offsetting AAS-mediated HDL suppression
07 Proven cardiovascular event and mortality reduction in large-scale clinical trials
08 Reduces triglycerides by 10-35%, beneficial during bulking phases or when using compounds that elevate TG
Tamoxifen
01 Blocks estrogen receptor signaling in breast tissue, preventing and treating gynecomastia
02 Stimulates LH and FSH production by antagonizing hypothalamic estrogen receptors
03 Restores endogenous testosterone production during post-cycle therapy
04 Partial estrogen agonist activity in bone preserves bone mineral density
05 Extremely long half-life allows for flexible dosing schedules
06 Decades of clinical use with a well-characterized safety and efficacy profile
07 Oral administration with no injections or reconstitution required
Side Effects
Rosuvastatin
Muscle pain and myalgia (5-10% of users) -- the most frequently reported complaint, ranging from mild soreness to significant discomfort
Headache
Nausea and abdominal discomfort
Weakness or fatigue
Constipation or diarrhea
Tamoxifen
Hot flashes and night sweats
Nausea or gastrointestinal discomfort
Mood swings, irritability, or emotional lability
Fatigue during initial weeks of use
Headache
Contraindications
Active liver disease or unexplained persistent elevations in hepatic transaminases
Known hypersensitivity to rosuvastatin or any excipients
Pregnancy and breastfeeding (Category X -- statins are teratogenic)
Concomitant use with cyclosporine (at all doses of rosuvastatin)
Severe renal impairment (eGFR <30 mL/min) for doses above 10 mg
History of deep vein thrombosis, pulmonary embolism, or other thromboembolic events
Known hypersensitivity to tamoxifen citrate or any excipients
Concurrent warfarin or coumarin-type anticoagulant therapy (increased bleeding risk)
Pregnancy or planned pregnancy (category D -- known teratogenic risk)
Pre-existing endometrial hyperplasia or uterine cancer
Severe hepatic impairment
Research Evidence
Rosuvastatin Tamoxifen
Status FDA Approved FDA Approved
References 4 studies 5 studies
Latest 2023 —
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.